News

STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, announces that it has been awarded a Biomedical…
Read More...

Genesis Therapeutics, a company pioneering artificial intelligence technologies to create medicines for patients with severe and unmet medical conditions, announced that it has entered…
Read More...

Nicoya Lifesciences, a global innovator of digital proteomics solutions for diagnostics and biotherapeutic discovery, announced the acquisition of LSK Technologies, a University of…
Read More...

Endo International plc announced that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables…
Read More...

Horizon Therapeutics plc announced the European Commission (EC) approval of UPLIZNA (inebilizumab) as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum…
Read More...

Supernus Pharmaceuticals, Inc. a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that…
Read More...

Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, announced the signing of an exclusive licensing agreement with Beijing…
Read More...

Inmagene Biopharmaceuticals announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis…
Read More...

GC Biopharma and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, announced that they…
Read More...

Plexium, Inc. (Plexium) and AbbVie have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for…
Read More...

SQZ Biotechnologies focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that the U.S. Food and Drug Administration (FDA) has granted Fast…
Read More...

Serenity Bioworks announces it has completed the acquisition of DC-TAB, a recombinant human HspB5 that was previously in clinical development for relapse-remitting multiple sclerosis.…
Read More...

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the European Commission (EC) has granted marketing authorization for VYDURA (rimegepant), a calcitonin…
Read More...

Daiichi Sankyo and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of adult patients with…
Read More...

RVAC Medicines Pte. Ltd. an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group ("CBC"), announced the completion of its series B financing, bringing the…
Read More...

Castle Biosciences, Inc. announced that it has completed its acquisition of AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the…
Read More...

Virpax Pharmaceuticals, Inc. a company specializing in developing non-addictive product candidates for pain management, CNS disorders and anti-viral indications, reported preclinical…
Read More...

Isleworth Healthcare Acquisition Corp. a special purpose acquisition company and Cytovia Holdings, Inc.("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to…
Read More...

STRIDE regimen of a single priming dose of tremelimumab added to Imfinzi is the first dual immune checkpoint blockade regimen to improve overall survival in a Phase III trial in…
Read More...